HSBC ups Ranbaxy to overweight on generic Lipitor announcement
HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in U.S. sales.
Ranbaxy shares were up 3.2 percent as of 0356 GMT.
Stocks More on Ranbaxy Laboratories
Be the first to comment.